摘要
目的探讨多西他赛与奥沙利铂化疗联合调强放射治疗(IMRT)中晚期食管癌的临床疗效。方法选取麻城市人民医院2015—2019年收治的Ⅱ~Ⅳ期食管癌患者80例,按照随机数字表法分为对照组与观察组,每组40例。对照组予以替吉奥胶囊联合IMRT治疗,观察组予以多西他赛与奥沙利铂联合IMRT治疗。比较2组近期疗效,治疗结束后1、2年生存率,并记录2组白细胞减少、红细胞减少、恶心呕吐、神经毒性、骨髓抑制、放射性肺炎等毒副作用发生情况,比较2组生活质量评分。结果观察组总有效率高于对照组(P<0.05)。治疗结束后1、2年观察组生存率高于对照组(P<0.05)。观察组恶心呕吐、骨髓抑制发生率低于对照组,神经毒性发生率高于对照组(P<0.05);2组白细胞减少、红细胞减少发生率比较,差异无统计学意义(P>0.05)。治疗结束时2组食管癌患者生活质量专用量表(QLQ-OES18)评分比较,差异无统计学意义(P>0.05);治疗结束后1、3、6个月观察组QLQOES18评分高于对照组(P<0.05)。结论多西他赛与奥沙利铂联合IMRT可明显提高中晚期食管癌患者近期疗效、生存率及生活质量,毒副作用可耐受。
Objective To investigate the clinical efficacy of docetaxel and oxaliplatin combined with intensity modulated radiation therapy(IMRT)for advanced esophageal cancer.Methods A total of 80 cases of patients with stageⅡ-Ⅳesophageal cancer were selected from 2015 to 2019 to in Macheng People's Hospital,which were divided into control group and observation group according to random number table,40 cases in each group.The control group was treated with tegafur capsule combined with IMRT,while the observation group was treated with docetaxel and oxaliplatin combined with IMRT.The short-term efficacy,1-year and 2-year survival rates after treatment were compared between the two groups.The incidence of adverse reactions such as leucopenia,erythrocytopenia,nausea and vomiting,neurotoxicity,myelosuppression,radiation pneumonitis and other adverse reactions were recorded,and the quality of life scores of the two groups were compared.Results The total effective rate of the observation group was higher than control group(P<0.05).The 1-year and 2-year survival rate of the observation group was higher than the control group(P<0.05).The incidence of nausea,vomiting and myelosuppression in the observation group was lower than the control group,and the incidence of neurotoxicity was higher than the control group(P<0.05);there was no significant difference in the incidence of leucopenia and erythrocytopenia between the two groups(P>0.05).At the end of treatment,there was no significant difference in qlq-oes18 score between the two groups(P>0.05);the qlq-oes18 score of the observation group was higher than the control group at 1,3 and 6 months after the treatment(P<0.05).Conclusion Docetaxel and oxaliplatin combined with IMRT can significantly improve the short-term efficacy,survival rate and quality of life of patients with advanced esophageal cancer,and the adverse reactions are tolerable.
作者
林峰
LIN Feng(Department of Cardiothoracic Surgery,Macheng People's Hospital,Huanggang 438300,China)
出处
《临床合理用药杂志》
2020年第27期11-13,共3页
Chinese Journal of Clinical Rational Drug Use
关键词
食管肿瘤
多西他赛
奥沙利铂
治疗结果
Esophageal neoplasms
Docetaxel
Oxaliplatin
Treatment outcome
